CN109071433A - 用作抗炎剂、抗转移剂和/或抗癌剂的氨基苯甲酸衍生物 - Google Patents

用作抗炎剂、抗转移剂和/或抗癌剂的氨基苯甲酸衍生物 Download PDF

Info

Publication number
CN109071433A
CN109071433A CN201780022811.3A CN201780022811A CN109071433A CN 109071433 A CN109071433 A CN 109071433A CN 201780022811 A CN201780022811 A CN 201780022811A CN 109071433 A CN109071433 A CN 109071433A
Authority
CN
China
Prior art keywords
cancer
compound
acetyl
alkyl
propioloyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780022811.3A
Other languages
English (en)
Chinese (zh)
Inventor
杰维斯·贝鲁布
卡洛斯·雷耶斯-莫雷诺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3R VALO SEC
Original Assignee
3R VALO SEC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3R VALO SEC filed Critical 3R VALO SEC
Publication of CN109071433A publication Critical patent/CN109071433A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
    • C07D207/452—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/404—2,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/456—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Pyrrole Compounds (AREA)
CN201780022811.3A 2016-04-11 2017-04-10 用作抗炎剂、抗转移剂和/或抗癌剂的氨基苯甲酸衍生物 Pending CN109071433A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662320654P 2016-04-11 2016-04-11
US62/320,654 2016-04-11
PCT/CA2017/050432 WO2017177316A1 (en) 2016-04-11 2017-04-10 Aminobenzoic acid derivatives for use as anti-inflammatory agents, anti-metastatic agents and/or anticancer agents

Publications (1)

Publication Number Publication Date
CN109071433A true CN109071433A (zh) 2018-12-21

Family

ID=60041299

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780022811.3A Pending CN109071433A (zh) 2016-04-11 2017-04-10 用作抗炎剂、抗转移剂和/或抗癌剂的氨基苯甲酸衍生物

Country Status (6)

Country Link
US (2) US10759754B2 (enExample)
EP (1) EP3442943B1 (enExample)
JP (1) JP2019513829A (enExample)
CN (1) CN109071433A (enExample)
CA (1) CA3020348A1 (enExample)
WO (1) WO2017177316A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114516819A (zh) * 2022-02-25 2022-05-20 顺毅宜昌化工有限公司 一种n,n’-二乙酰基肼的制备方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10787701B2 (en) 2010-04-05 2020-09-29 Prognosys Biosciences, Inc. Spatially encoded biological assays
CN118240918A (zh) 2013-06-25 2024-06-25 普罗格诺西斯生物科学公司 采用微流控装置的空间编码生物分析
CU24661B1 (es) 2018-01-17 2023-05-11 Aurigene Discovery Tech Ltd Compuestos de alquinileno sustituidos como agentes anticancerígenos
CA3021417A1 (en) * 2018-10-18 2020-04-18 3R Valo, S.E.C. Aminobenzoic acid derivatives for use as anti-inflammatory agents, anti-metastatic agents and/or anticancer agents
CN117447353A (zh) * 2023-09-21 2024-01-26 爱斯特（成都）生物制药股份有限公司 一种氘可来昔替尼中间体的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190002484A1 (en) * 2015-06-19 2019-01-03 Cytrx Corporation Delivery systems for controlled drug release

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3046301A (en) 1959-10-29 1962-07-24 Burroughs Wellcome Co Method of making chlorambucil
AU2005327921A1 (en) 2004-11-01 2006-08-31 University Of Southern California Novel compounds for treatment of cancer and disorders associated with angiogenesis function

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190002484A1 (en) * 2015-06-19 2019-01-03 Cytrx Corporation Delivery systems for controlled drug release

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FAHMY.M.M等: "《Novel antimicrobial organic thermal stabilizer and co-stabilizer for rigid PVC》", 《MOLECULES》 *
JOVANE HAMELIN-MORRISSETTE: "《Identification of an anti-inflammatory derivative with anti-cancer potential: The impact of each of its structural components on inflammatory responses in macrophages and bladder cancer cells》", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》 *
MASHOOQ A. BHAT1CA等: "《Design and Synthesis of N-Arylphthalimides as Inhibitors of Glucocorticoid-Induced TNF Receptor-Related Protein, Proinflammatory Mediators, and Cytokines in Carrageenan-Induced Lung Inflammation》", 《JOURNAL OF MEDICINAL CHEMISTRY》 *
STEFAN TASLER等: "《Non-competitive inhibitors of metabotropic glutamate receptor 5 (mGluR5)》", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114516819A (zh) * 2022-02-25 2022-05-20 顺毅宜昌化工有限公司 一种n,n’-二乙酰基肼的制备方法
CN114516819B (zh) * 2022-02-25 2024-02-27 顺毅宜昌化工有限公司 一种n,n’-二乙酰基肼的制备方法

Also Published As

Publication number Publication date
EP3442943A4 (en) 2019-03-20
US10759754B2 (en) 2020-09-01
WO2017177316A1 (en) 2017-10-19
EP3442943A1 (en) 2019-02-20
US20190127325A1 (en) 2019-05-02
EP3442943B1 (en) 2020-10-07
CA3020348A1 (en) 2017-10-19
US20210002222A1 (en) 2021-01-07
JP2019513829A (ja) 2019-05-30

Similar Documents

Publication Publication Date Title
CN109071433A (zh) 用作抗炎剂、抗转移剂和/或抗癌剂的氨基苯甲酸衍生物
JP7398156B2 (ja) Ｓｔａｔ３二機能性リン酸化部位を標的とするトリアロマティック化合物のクラスおよびその応用
JP2015536308A (ja) ガンの治療方法
Li et al. Novel harmine derivatives for tumor targeted therapy
Salamoun et al. 6-Amino [1, 2, 5] oxadiazolo [3, 4-b] pyrazin-5-ol derivatives as efficacious mitochondrial uncouplers in STAM mouse model of nonalcoholic steatohepatitis
JP5649652B2 (ja) 置換ヒドラジド類化合物及びその応用
Hamelin-Morrissette et al. Identification of an anti-inflammatory derivative with anti-cancer potential: The impact of each of its structural components on inflammatory responses in macrophages and bladder cancer cells
JP2021534215A (ja) 病的症状の治療における使用のための芳香族分子
CN104151391B (zh) 一种具有抗肿瘤作用的齐墩果酸衍生物及其制备方法和用途
JP2025527175A (ja) ウロリチン誘導体の治療的使用
CA2926928A1 (en) Aminobenzoic acid derivatives for use as anti-inflammatory agents, anti-metastatic agents and/or anticancer agents
US10793525B2 (en) 13-cis-RAMBA retinamides that degrade MNKs for treating cancer
US11370766B2 (en) Sulfonyl amidine as indoleamine-2,3-dioxygenase inhibitor, and preparation method therefor and use thereof
CA3021417A1 (en) Aminobenzoic acid derivatives for use as anti-inflammatory agents, anti-metastatic agents and/or anticancer agents
JP2021528368A (ja) Ｒａｓ腫瘍性タンパク質の阻害剤、その作製方法及びその使用方法
JP2019535751A (ja) 抗がん作用を有する化合物およびその製造方法ならびにその使用
TWI671284B (zh) 治療大腸直腸癌的化合物
RU2667906C1 (ru) Производное класса N-гликозидов индоло[2,3-а]пирроло[3,4-с]карбазол-5,7-дионов - N-{ 12-(β-D-ксилопиранозил)-5,7-диоксо-индоло[2,3-а]пирроло[3,4-с] карбазол-6-ил} пиридин-2-карбоксамид, обладающее цитотоксической и противоопухолевой активностью
JP6993721B2 (ja) 抗がん作用を有する化合物およびその製造方法ならびにその応用
HK40001514A (en) Aminobenzoic acid derivatives for use as anti-inflammatory agents, anti-metastatic agents and/or anticancer agents
JP6082488B1 (ja) カルボキシル基により酸性になったｐａｋ１遮断剤のエステル体の調製および癌やその他のｐａｋ１依存性疾患治療への応用
EP4316476A1 (en) Anticancer agents based on cyclopentenones
CN103374001B (zh) 咪唑并三嗪类mTOR抑制剂
BR102022021429A2 (pt) Utilização de derivados de 5-amino-4-calcogenilpirazóis como agentes antitumorais para câncer de bexiga
CN120423991A (zh) 一种β-硒代丙酰胺类化合物或其药学上可接受的盐或其异构体、合成方法及其在制备治疗或预防铁死亡相关疾病药物中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40001514

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20181221

WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 40001514

Country of ref document: HK